Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 13 | 2024 | 938 | 1.700 |
Why?
|
| Liver Neoplasms | 13 | 2024 | 1319 | 1.520 |
Why?
|
| Liver Cirrhosis | 14 | 2024 | 833 | 1.290 |
Why?
|
| Early Detection of Cancer | 4 | 2024 | 356 | 0.770 |
Why?
|
| Liver Transplantation | 6 | 2020 | 1038 | 0.750 |
Why?
|
| Alcohol Drinking | 2 | 2024 | 339 | 0.710 |
Why?
|
| Hepatitis C | 4 | 2023 | 364 | 0.700 |
Why?
|
| Alcoholic Beverages | 1 | 2019 | 18 | 0.640 |
Why?
|
| End Stage Liver Disease | 3 | 2018 | 182 | 0.630 |
Why?
|
| Religion | 1 | 2019 | 46 | 0.620 |
Why?
|
| Liver Diseases | 2 | 2018 | 366 | 0.560 |
Why?
|
| Hepacivirus | 3 | 2016 | 241 | 0.550 |
Why?
|
| Alcoholism | 1 | 2019 | 230 | 0.530 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 136 | 0.500 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 89 | 0.490 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 14 | 0.490 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 57 | 0.460 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 78 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2016 | 746 | 0.410 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 57 | 0.400 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 433 | 0.320 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 397 | 0.290 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2008 | 64 | 0.280 |
Why?
|
| Veterans | 1 | 2018 | 1751 | 0.270 |
Why?
|
| alpha-Fetoproteins | 2 | 2024 | 132 | 0.270 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1460 | 0.270 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 223 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2024 | 6083 | 0.250 |
Why?
|
| Quality Improvement | 2 | 2022 | 638 | 0.250 |
Why?
|
| Risk Factors | 11 | 2024 | 10134 | 0.230 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2024 | 13 | 0.230 |
Why?
|
| Protein Precursors | 1 | 2024 | 150 | 0.220 |
Why?
|
| Humans | 27 | 2024 | 124311 | 0.210 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 244 | 0.200 |
Why?
|
| Graft Survival | 2 | 2014 | 527 | 0.190 |
Why?
|
| Middle Aged | 14 | 2024 | 26428 | 0.190 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2020 | 44 | 0.170 |
Why?
|
| Program Development | 1 | 2020 | 187 | 0.160 |
Why?
|
| History, 15th Century | 1 | 2019 | 14 | 0.160 |
Why?
|
| United States | 4 | 2024 | 10757 | 0.160 |
Why?
|
| History, 16th Century | 1 | 2019 | 27 | 0.160 |
Why?
|
| History, Medieval | 1 | 2019 | 27 | 0.160 |
Why?
|
| History, Ancient | 1 | 2019 | 54 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 2122 | 0.160 |
Why?
|
| Pentanoic Acids | 1 | 2018 | 3 | 0.150 |
Why?
|
| Caspase Inhibitors | 1 | 2018 | 31 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2020 | 183 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 120 | 0.150 |
Why?
|
| Cystatin C | 1 | 2018 | 51 | 0.140 |
Why?
|
| Obesity | 3 | 2024 | 2250 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 42 | 0.140 |
Why?
|
| Male | 16 | 2024 | 60976 | 0.140 |
Why?
|
| Female | 17 | 2024 | 66248 | 0.140 |
Why?
|
| Aged | 10 | 2024 | 19456 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1659 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2024 | 3371 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3134 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2016 | 14 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 545 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 234 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 14 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2016 | 160 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2015 | 54 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 484 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2018 | 539 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 668 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 95 | 0.120 |
Why?
|
| Platelet Count | 2 | 2024 | 136 | 0.110 |
Why?
|
| Time Factors | 2 | 2014 | 6264 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12279 | 0.110 |
Why?
|
| Incidence | 4 | 2024 | 3085 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 107 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 110 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 143 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 180 | 0.110 |
Why?
|
| Arterial Pressure | 1 | 2014 | 101 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 200 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 358 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2014 | 228 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 240 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2014 | 677 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 324 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1154 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1425 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 440 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16223 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 566 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 3590 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 2551 | 0.080 |
Why?
|
| Portal Pressure | 1 | 2008 | 5 | 0.080 |
Why?
|
| Decision Trees | 1 | 2008 | 49 | 0.070 |
Why?
|
| Hepatic Veins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Sclerotherapy | 1 | 2008 | 40 | 0.070 |
Why?
|
| Ligation | 1 | 2008 | 135 | 0.070 |
Why?
|
| Age Factors | 1 | 2014 | 2804 | 0.070 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 93 | 0.070 |
Why?
|
| Biomarkers | 3 | 2024 | 2976 | 0.070 |
Why?
|
| Esophagoscopy | 1 | 2008 | 156 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2008 | 122 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2024 | 109 | 0.060 |
Why?
|
| Prothrombin | 1 | 2024 | 24 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2024 | 44 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 122 | 0.060 |
Why?
|
| Lipase | 1 | 2024 | 89 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2024 | 152 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3267 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 36 | 0.050 |
Why?
|
| North America | 1 | 2024 | 237 | 0.050 |
Why?
|
| Adolescent | 3 | 2020 | 19350 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 333 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 14074 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 4554 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 1320 | 0.040 |
Why?
|
| Adult | 3 | 2018 | 29357 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 359 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 2895 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 122 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 2029 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 214 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5107 | 0.040 |
Why?
|
| Keratin-18 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 2038 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 216 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 47 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 221 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 241 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 2870 | 0.040 |
Why?
|
| Child | 2 | 2015 | 24514 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2020 | 191 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 442 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 334 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2024 | 1530 | 0.030 |
Why?
|
| Triglycerides | 1 | 2019 | 567 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 41 | 0.030 |
Why?
|
| Creatinine | 1 | 2018 | 382 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 330 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2613 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1618 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 383 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1267 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2016 | 539 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1482 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 286 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 1411 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1415 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3726 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2020 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4729 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6467 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 8972 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3062 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8180 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 12474 | 0.010 |
Why?
|